Premium
In Vitro Testing for Hypersensitivity‐Mediated Adverse Drug Reactions: Challenges and Future Directions
Author(s) -
Elzagallaai A A,
Koren G,
Bend J R,
Rieder M J
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.155
Subject(s) - drug reaction , drug , clinical pharmacology , medicine , in vitro , pharmacology , gold standard (test) , presentation (obstetrics) , adverse effect , intensive care medicine , chemistry , surgery , biochemistry
Drug hypersensitivity reactions (DHRs) are uncommon but potentially fatal adverse events. Their diagnosis and prediction are difficult given their variable presentation and the overlap of symptoms with those of other clinical conditions. Systemic rechallenge is considered the gold standard for the diagnosis of DHRs; however, this may have severe consequences. In vitro tests are currently not sufficiently reliable to provide the basis for clinical decisions. This article summarizes the challenges associated with in vitro testing for DHRs. Clinical Pharmacology & Therapeutics (2011) 90 3, 455–460. doi: 10.1038/clpt.2011.155